693 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
AMGN Amgen Inc. $200.81 $129.98B N/A
Article Searches
Top Research Reports for Apple, Amgen & United Technologies http://www.zacks.com/research-daily/364738/top-research-reports-for-apple-amgen-united-technologies?cid=CS-ZC-FT-364738 Mar 26, 2019 - Top Research Reports for Apple, Amgen & United Technologies
Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent http://www.zacks.com/stock/news/360917/regeneron-sanofi-get-ec-nod-for-label-expansion-of-praluent?cid=CS-ZC-FT-360917 Mar 18, 2019 - Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.
Roche Gets Approval for Label Expansion of MabThera in Europe http://www.zacks.com/stock/news/359892/roche-gets-approval-for-label-expansion-of-mabthera-in-europe?cid=CS-ZC-FT-359892 Mar 15, 2019 - Roche (RHHBY) gets EC approval for the label expansion of its legacy RA drug, MabThera for pemphigus vulgaris.
AMGN: BMO Capital Markets starts at Outperform http://www.briefing.com/investor/popuppages/articlepopup.aspx?articleId=UD20190315120125 Mar 15, 2019 - BMO Capital Markets issues rating change for AMGN
Roche Receives EC Approval for Label Expansion of Hemlibra http://www.zacks.com/stock/news/359564/roche-receives-ec-approval-for-label-expansion-of-hemlibra?cid=CS-ZC-FT-359564 Mar 14, 2019 - Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.
Roche's (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer http://www.zacks.com/stock/news/358936/roches-rhhby-tecentriq-gets-fda-approval-for-breast-cancer?cid=CS-ZC-FT-358936 Mar 12, 2019 - Roche (RHHBY) gets FDA approval for immuno-oncology drug, Tecentriq in combination with Abraxane for the treatment of breast cancer.
Is iShares Nasdaq Biotechnology Index Fund a Buy? https://www.fool.com/investing/2019/03/11/is-ishares-nasdaq-biotechnology-index-fund-a-buy.aspx?source=iedfolrf0000001 Mar 11, 2019 - The largest biotech ETF looks good for investors who don't mind the industry's manic behavior.
Lilly's Emgality Gets FDA Priority Review for Cluster Headache http://www.zacks.com/stock/news/357965/lillys-emgality-gets-fda-priority-review-for-cluster-headache?cid=CS-ZC-FT-357965 Mar 06, 2019 - Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.
Ligand Sells Promacta Rights for $827M, Updates '19 View http://www.zacks.com/stock/news/357855/ligand-sells-promacta-rights-for-%24827m-updates-19-view?cid=CS-ZC-FT-357855 Mar 06, 2019 - Ligand Pharmaceuticals (LGND) announces sale of all rights to Novartis' Promacta, including royalty payments on global sales, to Royalty Pharma.
3 Big Pharmas Trying to Pop the Rebate Bubble https://www.fool.com/investing/2019/03/06/3-big-pharmas-trying-to-pop-the-rebate-bubble.aspx?source=iedfolrf0000001 Mar 06, 2019 - Pharmaceutical companies are suddenly eager to lower drug prices.

Pages: 12345678910...70

<<<Page 5>